Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01523223 · ClinicalTrials.gov registry record · Phase 1
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
A Phase 1 study, sponsored by Robert Lowsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01523223 is a Phase 1 study that has completed, run by Robert Lowsky. The registered enrollment target is 16 participants.
The verdict
NCT01523223, a Phase 1 study, has completed, sponsored by Robert Lowsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies. Giving low dose of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-cancer effects). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect
Interventions
- BIOLOGICAL therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01523223
The ClinicalTrials.gov registry entry for NCT01523223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Lowsky, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic allogeneic lymphocytes is the first listed.
NCT01523223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01523223 about?
NCT01523223 is a clinical study titled "Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies". This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies. Giving low dose of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's...
What is the current status of trial NCT01523223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01523223?
The interventions under investigation include: therapeutic allogeneic lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01523223?
This trial is sponsored by Robert Lowsky, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.